We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Decision on Cordran Provides Lifeline for IGI Labs
FDA Decision on Cordran Provides Lifeline for IGI Labs
June 18, 2013
In response to a citizen petition from struggling startup IGI Labs, the FDA has determined that Aqua Pharmaceuticals’ discontinued topical corticosteroid ointment Cordran was not withdrawn from the market for safety and efficacy reasons, clearing the way for ANDA approval.